Posts

OrbiMed raises $3B across two healthcare funds

on
OrbiMed announced on October 15, 2026, that it raised $3 billion in commitments across two new private equity funds. OrbiMed Private Investments X raised more than $1.9 billion for life sciences venture investments in the U.S. and Europe. OrbiMed Asia Partners VI raised more than $1 billion for healthcare growth equity and venture capital across Asia—reportedly the firm’s largest Asia-focused fund to date. Both funds will target biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. Investors include institutions, endowments, foundations, pension funds, sovereign wealth funds, and family offices. Sources: OrbiMed Raises $3 Billion Across Global and Asia Private ... 奥博资本Archives - OrbiMed OrbiMed’s largest-ever Asian fund contributes to $3B war chest OrbiMed Banks $3 Billion for Two Healthcare Venture Funds Orbimed News Archives News & Insights OrbiMed Raises $3 Billion for Global Healthcare Investments OrbiMed Raises $3...

Lakefront sells cell therapy pipeline to Armed Cell

on

NorthStar partners with Quarkmed to support Ac-225 drug filings in China

on

Iambic raises $150 million in IPO to advance cancer drug pipeline

on

AstraZeneca and insitro partner on AI-led liver and heart drug discovery

on

Vanda puts social-anxiety drug program on hold after Phase 3 setback

on

Verastem’s early KRAS drug results draw bold CEO claim

on

Rakovina secures exclusivity for AI-optimized KT-5000 profile

on

Shared barriers keep Leqembi and Kisunla uptake challenging

on

Verastem’s VS-7375 posts early pancreatic cancer responses, setting up a KRAS rivalry

on

FDA proposes a more consistent—but tailored—approach to rare-disease drugs

on

OMass raises $310 million to advance experimental adrenal-disorder drug

on

DaltonTx receives Gates Foundation grant for AI-powered TB drug discovery

on